Comprehensive Hematology Oncology

Comprehensive Hematology Oncology Logo

Clinical Research Studies

First Line Lung Cancer

  1. A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer (SUNRAY-01)
    1. ClinicalTrials.gov ID NCT06119581
  2. Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
    1. ClinicalTrials.gov ID NCT05899608
  3. A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC
    1. ClinicalTrials.gov ID NCT06627647
  4. Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer (SUNRAY-02)
    1. ClinicalTrials.gov ID NCT06890598

Second-line Lung Cancer

  1. A Phase 2, Open-Label, Randomized, Global Study of Three Telisotuzumab Vedotin Regimens in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer
    1. ClinicalTrials.gov ID NCT06568939
  2. Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor (ARTEMIA)
    1. ClinicalTrials.gov ID NCT06472245
  3. Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations (TROPION-Lung17)
    1. ClinicalTrials.gov ID NCT07291037

Breast Cancer

  1. An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
    1. ClinicalTrials.gov ID NCT05952557
  2. Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
    1. ClinicalTrials.gov ID NCT06797635
  3. A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician’s Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
    1. ClinicalTrials.gov ID NCT06312176
  4. A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant Plus a CDK4/6 Inhibitor, in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
    1. ClinicalTrials.gov ID NCT06065748
  5. A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+, HER2-, Early Breast Cancer With High Risk of Recurrence (ELEGANT)
    1. ClinicalTrials.gov ID NCT06492616

Head and Neck Cancer

  1. A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma (JADE)
    1. ClinicalTrials.gov ID NCT06256588

Urothelial Cancer

  1. Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
    1. ClinicalTrials.gov ID NCT07129993

Solid Tumor Cancer

  1. Study of STP938 in Advanced Solid Tumours
    1. ClinicalTrials.gov ID NCT06297525
  2. A Phase 1/1b Study of IAM1363 in HER2 Cancers
    1. ClinicalTrials.gov ID NCT06253871

Observational Trials

  1. Breast Cancer-Minimal/Molecular Residual Disease Detection and Therapy Monitoring in Patients with Early Stage TNBC-Phase I (B-STRONGER-I)
    1. ClinicalTrials.gov ID NCT06230185
  2. Molecular Residual Disease in Solid Tumors: A Prospective Study to Collect Clinical Data and Biospecimens to Support Discovery and Development of Cancer Biomarkers
    1. ClinicalTrials.gov ID NCT06605404
  3. Collection of Biological Specimens and Associated Health Information for Secondary Research in Future Studies
    1. ClinicalTrials.gov ID NCT06369441
  4. Effectiveness of T-DXd Across HER2-positive Solid Tumors in Patients Who Have Received Prior Systemic Treatment and Have no Satisfactory Alternative Treatment Options: A Hybrid Observational Study
    1. ClinicalTrials.gov ID NCT07124000